Pfizer raised profit estimates for 2025 thanks to cost cuts, despite falling COVID product revenue and patent expirations.
Sanziana Georgescu
Economy
sursa foto: shutterstock.com
Always see our news on Google
Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
15:00
Insurance company accused of violating religious freedom after requesting the removal of a Christian message from its vehicle.
14:59
The Ministry of Health announced the signing of 49 additional acts for the continuation of investments in health.
14:52
FAO: The global food price index reached its highest level in July in the last three years
14:43
The authorities in France will simulate a national power outage in 2027 to assess the country's preparedness in case of an energy crisis.
14:42
A 55-year-old man from Bucharest, who painted a heart with graffiti spray on a rock on the Transfăgărășan, has been identified by the police. He risks a fine of up to 6,000 lei.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
